PostExposure medicines(PEP) for HIV

PostExposure medicines(PEP) for HIV PEP =Post Exposure Prophylaxis for HIV typically consists of a 28-day regimen. Common regimens include:

Tenofovir disoproxil fumarate (TDF) 300 mg + Emtricitabine (FTC) 200 mg + Raltegravir 400 mg twice daily (preferred for most exposures). – Alternatively, TDF 300 mg + FTC 200 mg + Dolutegravir 50 mg once daily (if raltegravir is unavailable or contraindicated). – For higher-risk exposures, boosted protease inhibitors (e.g., darunavir/cobicistat) may be added. – Rationale: Guidelines (e.g., CDC, WHO) recommend these regimens due to high efficacy and tolerability. – Effectiveness:
If initiated within 72 hours of exposure, PEP reduces HIV transmission risk by ~80%. – Adherence to the full 28-day course is critical for effectiveness. – Rationale: Early initiation and adherence prevent viral replication and integration. – Side Effects:
Common: Nausea, fatigue, headache, diarrhea (usually mild and transient). – Less common: Elevated liver enzymes, renal impairment (with TDF), or rash (with integrase inhibitors). – Severe: Rare, but monitor for hypersensitivity reactions or lactic acidosis (with older NRTIs). – Rationale: Side effects are generally manageable; dose adjustments or regimen switches may be needed.